Vaccines

A*STAR researchers develop a smarter delivery system for mRNA vaccines that boosts their targeting abilities and biological safety.

A new ‘liquid lipid’ approach that penetrates the nose’s mucus barrier could lead to needle-free, nasal spray-based mRNA vaccines.

A*STAR researchers discover how subtle changes to a packaging component of mRNA vaccines can boost their efficacy and safety.

Antibodies in mucous membranes may be key in protecting against SARS-CoV-2 variants, pointing to the need for COVID-19 vaccines that target these antibody responses.

A new streamlined method for purifying lab-grown viruses could accelerate vaccine production, allowing manufacturers to respond rapidly to emerging viral threats

Data shows that antibodies produced as part of the COVID-19 immune response can neutralize a more transmissible variant of SARS-CoV-2.

The discovery of how aging impacts memory T cells may unlock novel therapeutic targets to boost immune protection in older adults.

A*STAR researchers have identified specific sites in the surface protein of influenza viruses that allow the pathogen to adapt to different host organisms.

Targeted mutagenesis is being used to create live-attenuated vaccines against the chikungunya virus.

A*STAR scientists have found a way to strengthen the immune response to adenovirus infection using engineered antibodies.

Powerful
new technologies shed light on the origin and maturation process of key immune
system cells

A more efficient production process for influenza vaccines could help to cope with future pandemics